A phase I/II trial by Vadhan-Raj et al., in 29 patients with asymptomatic, relapsed, or plateau phase multiple myeloma showed a decrease in expression of NF-κB, COX-2, and STAT3 in peripheral blood mononuclear cells and stable maintenance of disease [304]. The gene discussed is STAT3; the disease is AL amyloidosis.